The main points
-
Scientists have developed Diacaca, a stable oral drug obtained from carnostic acid rosemary to combat Alzheimer’s disease, reducing inflammation and oxidative stress in the brain.
-
In pre-clinical mice studies, Diacca recreated memory function, increased synaptic density and reduced the key biological markers of the key Alzheimer, including amyloid β and phosphorytilus-proteins.
-
The drug is only activated in the inflammatory areas of the brain and uses a compound that the FDA is already safe, which can simplify the way to clinical trials of human clinical trials and to allow the existing therapy.
New studies show that Rosemary has more benefits than only to improve your other steak aroma and taste. It turns out that this can also be a secret ingredient in the fight against Alzheimer’s disease.
February Researchers at the SCRIPPS Research Institute have published their findings of a new compound called Diacca, which they designed as a verbal medicine that one day could help treat Alzheimer’s disease. As the researchers explain, Diacca is obtained from carnostic acid (CA), a natural antioxidant found in rosemary and sage, already known as reducing inflammation and oxidative stress – two factors strongly related to the course of Alzheimer’s disease in previous studies.
The authors explained in the statement that carnosin acid works by activating enzymes in the body’s “natural defense system”. Really, this acid is too unstable to serve as a promising drug therapy. However, they managed to create a stable form called Diacca, which they believe were once consumed, converted into a carnose acid in the intestine and then absorbed into the bloodstream.
Their work, published in Antioxidants magazine, showed that in the mouse models, Diacca can give the brain therapeutic doses of carnosic acid, resulting in improved “memory and synaptic density”. Their analysis also revealed a significant decrease in inflammation in the brain after treatment.
“In the fight against inflammation and oxidative stress with this Diacca compound, we actually increased the number of synapses in the brain,” shared Stuart Lipon, MD, PhD, senior author and SCRIPPS professor. “We also eliminated other incorrectly folded or summarized proteins such as phosphorylated for you and amyloid-β, which are believed to cause Alzheimer’s disease and serve as biomarkers of the disease process.”
And probably the most convincing scientists have noted that the drug is only activated by the inflammation it directs, so it only affects the areas of the brain that combat inflammatory damage and thus restrict side effects.
Related: With regular eating breakfast you can protect against age -related brain changes, studio findings
“We did several different memory tests, and they were all improved with the medicine,” Lipon added. “And that not only slowed down the downturn; it practically improved to normal.”
These researchers also have more good news. They noted that carnosin acid is already included in the US Food and Drug Administration as “usually considered safe” (Gras), which can make it easier for people to perform clinical trials because the ingredient itself will not require additional FDA approval.
According to Lipton, Diacca can work well with the treatments of other Alzheimer, adding that “it can force the existing treatment of amyloid antibodies to work better by subtracting or restricting their side effects.” Still, he does not stop with Alzheimer. Lipon hopes to investigate its use for other inflammatory disorders, including type 2 diabetes, heart disease and Parkinson’s disease in the future.
Read the original article about food and wine